HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Mark B. Orringer Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Orringer, M. B. Articles by Bromberg, J. Search for Related Content PubMed PubMed Citation Articles by Orringer, M. B. Articles by Bromberg, J.

Ann Thorac Surg 1990;49:348-355
© 1990 The Society of Thoracic Surgeons

---

Articles

Chemotherapy and radiation therapy before transhiatal esophagectomy for esophageal carcinoma

^a Section of Thoracic Surgery, Department of Surgery, Division of Hematology-Oncology, Department of Internal Medicine, and Department of Radiation Oncology, University of Michigan Medical Center, Ann Arbor, Michigan USA
^b Department of Biostatistics, School of Public Health, Ann Arbor, Michigan USA

^_* Address reprint requests to Dr Orringer, Section of Thoracic Surgery, University of Michigan Medical Center, 1500 E Medical Center Dr, 2120 TC/0344, Ann Arbor, MI 48109.

Recent efforts to improve survival in patients with esophageal carcinoma have combined both systemic and local therapy. From October 1985 to October 1987, 43 patients with local-regional esophageal cancer (adenocarcinoma in 21, squamous cell in 22) were treated with cisplatin, vinblastine, and 5-fluorouracil chemotherapy concurrent with 4,500 cGy radiation therapy for 21 days before transhiatal esophagectomy 3 weeks later. Two patients died of chemotherapy/radiation therapy toxicity. Forty-one completed preoperative chemotherapy/radiation therapy. At operation, 2 patients had incurable metastatic disease; 39 underwent transhiatal esophagectomy. Eleven patients had no residual tumor in the resected specimen for a 27% (11 of 41) pathological complete response rate. Preoperative chemotherapy/radiation therapy resulted in no increased perioperative morbidity as compared with our historical controls. One patient died postoperatively of an unrecognized brain metastasis (2% operative morbidity). At a median follow-up of 27 months, 20 patients (47%) are alive and clinically disease-free and 21 have died, 19 from progression of their carcinoma. The median survival time for all 43 patients is 29 months (Kaplan-Meier estimate), and cumulative survival is 72% at 12 months, 60% at 24 months, and 46% at 36 months. All 11 patients with a complete response are alive at a median follow-up of 36 months, and all are disease-free. The 2-year survival of 60% of this group as compared with 32% in our earlier patients treated with transhiatal esophagectomy alone suggests that intensive combined modality therapy improves survival in these patients. A randomized prospective trial is now in progress.

This article has been cited by other articles:

				Y. Nishimura, H. Osugi, K. Inoue, N. Takada, M. Takamura, and H. Kinosita Bronchoscopic Ultrasonography in the Diagnosis of Tracheobronchial Invasion of Esophageal Cancer J. Ultrasound Med., January 1, 2002; 21(1): 49 - 58. [Abstract] [Full Text] [PDF]

				J. I. Lew, W. E. Gooding, U. Ribeiro Jr, A. V. Safatle-Ribeiro, and M. C. Posner Long-term Survival Following Induction Chemoradiotherapy and Esophagectomy for Esophageal Carcinoma Arch Surg, July 1, 2001; 136(7): 737 - 742. [Abstract] [Full Text] [PDF]

				M. Yasunaga, Y. Tabira, K. Nakano, S. Iida, N. Ichimaru, N. Nagamoto, and T. Sakaguchi Accelerated growth signals and low tumor-infiltrating lymphocyte levels predict poor outcome in T4 esophageal squamous cell carcinoma Ann. Thorac. Surg., November 1, 2000; 70(5): 1634 - 1640. [Abstract] [Full Text] [PDF]

				C. E. Reed Surgical Management of Esophageal Carcinoma Oncologist, April 1, 1999; 4(2): 95 - 105. [Abstract] [Full Text]

				H. Nagawa, Y. Seto, O. Kobori, and T. Muto An Experience of Treatment for Patients With Thoracic Esophageal Cancer Invading Adjacent Organs Jpn. J. Clin. Oncol., August 1, 1997; 27(4): 248 - 250. [Abstract] [Full Text] [PDF]

				D. R. Jones, F. C. Detterbeck, T. M. Egan, L. A. Parker Jr, S. A. Bernard, and J. E. Tepper Induction Chemoradiotherapy Followed by Esophagectomy in Patients With Carcinoma of the Esophagus Ann. Thorac. Surg., July 1, 1997; 64(1): 185 - 192. [Abstract] [Full Text]

				C. E. Reed Adjuvant Therapy of Esophageal Cancer Ann. Thorac. Surg., July 1, 1997; 64(1): 280 - 281. [Full Text]

				J. M. Kane III, L. L. Shears, U. Ribeiro, M. R. Clark, M. Peterson, R. J. Landreneau, and M. C. Posner Is Esophagectomy Following Upfront Chemoradiotherapy Safe and Necessary? Arch Surg, May 1, 1997; 132(5): 481 - 486. [Abstract] [PDF]

				M. D. Iannettoni, S. S. Lee, M. R. Bonnell, T. L. Sell, R. I. Whyte, M. B. Orringer, and D. G. Beer Detection of Barrett's Adenocarcinoma of the Gastric Cardia With Sucrase Isomaltase and p53 Ann. Thorac. Surg., November 1, 1996; 62(5): 1460 - 1465. [Abstract] [Full Text]

				E. Laterza, C. Griso, U. S. Urso, G. de' Manzoni, M. Malago, C. Oliani, and C. Cordiano Induction therapy for squamous carcinoma of thoracic esophagus Ann. Thorac. Surg., May 1, 1994; 57(5): 1126 - 1132. [Abstract] [PDF]

				W. T. Vigneswaran, V. F. Trastek, P. C. Pairolero, C. Deschamps, R. C. Daly, and M. S. Allen Transhiatal esophagectomy for carcinoma of the esophagus Ann. Thorac. Surg., October 1, 1993; 56(4): 838 - 846. [Abstract] [PDF]

				Z. Steiger Perioperative multimodality management of esophageal cancer: Therapeutic or investigational? Ann. Thorac. Surg., March 1, 1990; 49(3): 345 - 346. [PDF]